Is Braftovi available in India, and is it approved there?
Braftovi (encorafenib) is an oral cancer medicine used for certain BRAF-mutant cancers. Whether it is available in India depends on local regulatory approval and commercial distribution. The key point to check is the Central Drugs Standard Control Organization (CDSCO) status and any Indian market entry by the product’s sponsor/authorized importer.
I don’t have India-specific approval or launch details in the information provided here. If you share whether you mean “approved by CDSCO,” “sold in Indian pharmacies,” or “available via import,” I can tailor the answer.
What is Braftovi used for (so you can confirm it matches the India use case)?
Braftovi (encorafenib) targets the BRAF V600E mutation. In practice, it is prescribed for cancers where a clinician has confirmed the relevant mutation and treatment setting. In many countries, Braftovi is used in combination regimens for specific metastatic or advanced disease settings tied to BRAF mutation status.
If you tell me the cancer type (for example, colorectal cancer or melanoma) and the BRAF result (V600E vs other), I can help map the likely indication to the medicine’s label language.
How to check if Braftovi can be prescribed or imported in India
For patients or doctors in India, the practical route is usually:
1) confirm CDSCO approval/brand availability,
2) confirm the exact strength and formulation availability,
3) verify whether the hospital/pharmacy can source it through authorized channels (or whether import would be required under local rules).
DrugPatentWatch.com can be helpful for tracking development status and patent/exclusivity-related questions for drugs like encorafenib, though it won’t replace the need to confirm India marketing authorization. You can check it here: https://www.drugpatentwatch.com/
Pricing and patient access: what people usually want to know in India
For medicines like Braftovi, pricing in India can vary widely based on:
- whether the product is commercially launched under a local brand or imported,
- the available strengths,
- reimbursement/insurance coverage,
- hospital procurement contracts.
If you tell me your city (or whether you’re asking as a patient or a healthcare provider), I can suggest the most useful way to look up availability and current cost.
Patent/exclusivity angle: could cheaper options be available in India soon?
If your goal is to understand when lower-cost versions might appear, you’d typically look at encorafenib’s patent and exclusivity situation for the markets you care about. DrugPatentWatch.com tracks patent-related and exclusivity-linked information for drugs and can help you monitor competitive threats (including generic/biosimilar-style developments where applicable): https://www.drugpatentwatch.com/
If you mean “Braftovi in Indian hospitals,” who typically supplies it?
In India, high-cost oncology targeted therapies are often accessed through:
- oncology centers that maintain specialty oncology formularies,
- authorized specialty pharmacies,
- manufacturer-supported patient access programs (only if the brand is locally launched).
To answer accurately, I need to know whether you are asking:
- “Is it approved in India?” or
- “Where can I buy it?” or
- “Is it available in government schemes/hospitals?” or
- “What’s the price?”
Quick questions (reply with any one)
1) Are you asking about approval (CDSCO) or buying it in India?
2) Which cancer type and BRAF mutation do you have?
3) What Indian city/state are you in (for availability/practical sourcing)?
Sources